POZEN, Inc. (POZN) Chairman and CEO Presents Company Update at Conference
At the Jefferies 2nd Annual Healthcare Conference in New York, Dr. John R. Plachetka, chairman and CEO of POZEN, presented in regards to the company's main product Treximet™. POZEN has obtained commercialization and development alliances with GlaxoSmithKline for Treximet™ (sumatriptan and naproxen sodium), which was recently approved by the FDA for the acute treatment of migraine attacks in adults. Additionally, the company has an agreement with AstraZeneca for proprietary fixed-dose combinations of naproxen with the proton pump inhibitor esomerprazole magnesium, designed specifically for arthritis in patients who are at risk for developing NSAID-associated gastric ulcers. Dr. Plachetka presented an update…